An open-label first-line study of Xeloda [capecitabine] in combination with cisplatin on overall treatment response in patients with metastatic nasopharyngeal cancer.

Trial Profile

An open-label first-line study of Xeloda [capecitabine] in combination with cisplatin on overall treatment response in patients with metastatic nasopharyngeal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2010

At a glance

  • Drugs Capecitabine; Cisplatin
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Jun 2010 Actual patient number changed from 42 to 45 as reported by Roche.
    • 19 Dec 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 01 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top